英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
002218查看　002218　在百度字典中的解释百度英翻中〔查看〕
002218查看　002218　在Google字典中的解释Google英翻中〔查看〕
002218查看　002218　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • NEXLIZET® NEXLETOL® HCP Information - Official Site
    In the cardiovascular outcomes trial, the rates were 1 2% for bempedoic acid and 0 9% for placebo Discontinue NEXLIZET or NEXLETOL at the first sign of tendon rupture Consider alternative therapy in patients who have a history of tendon disorders or tendon rupture
  • FDA Expands Label for Bempedoic Acid to Reduce Cardiovascular . . .
    The FDA has approved a broad new label expansion for bempedoic acid (Nexletol; Esperion Therapeutics) and bempedoic acid and ezetimibe (Nexlizet; Esperion) to reduce cardiovascular risk and expanded the low-density lipoprotein-C (LDL-C) lowering in both primary and secondary prevention patients, according to the press release Furthermore, the approval also includes an indication for primary
  • Nexletol shows CLEAR benefit in cardiovascular outcome trial
    New data for Esperion’s cholesterol lowering daily pill Nexletol, used when statins are not working in people at risk of a heart attack, could inject some momentum into the drug’s slow rollout
  • label - accessdata. fda. gov
    In the cardiovascular outcomes trial [see Clinical Studies (14 1)], 16 4% of NEXLETOL-treated patients experienced clinically significant hyperuricemia reported as an adverse reaction (versus 8 2% placebo) Elevated blood uric acid may lead to the development of gout
  • U. S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET . . .
    ANN ARBOR, Mich , March 22, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded
  • U. S. FDA Approves Broad New Labels for NEXLETOL and . . . - DAIC
    April 1, 2024 — Esperion announced that the United States Food and Drug Administration (FDA) has approved broad new label expansions for NEXLETOL (bempedoic acid) Tablets and NEXLIZET (bempedoic acid and ezetimibe) Tablets based on positive CLEAR Outcomes data that include indications for cardiovascular risk reduction and expanded LDL-C lowering in both primary and secondary prevention
  • U. S. FDA Approves Broad New Labels for Esperion’s NEXLETOL . . .
    U S FDA approves broad new labels for NEXLETOL® (bempedoic acid) Tablets and NEXLIZET® (bempedoic acid and ezetimibe) Tablets to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use
  • Cardiovascular therapeutic targets of sodium-glucose co . . .
    Sodium-glucose co-transporter 2 (SGLT2) inhibitors are oral antidiabetic agents that have shown significant improvements in cardiovascular and renal o…
  • FDA Expands Labels for Nexletol, Nexlizet to Prevent Heart . . .
    U S FDA approves broad new labels for Nexletol and Nexlizet to prevent heart attacks and cardiovascular procedures in both primary and secondary prevention patients, regardless of statin use
  • FDA Expands Bempedoic Acid Label to Include Primary . . .
    The US Food and Drug Administration on March 22, 2024, approved broad label expansions for bempedoic acid (Nexletol) and bempedoic acid with ezetimibe (Nexlizet) tablets to include indications for expanded LDL-C lowering in both primary and secondary prevention of cardiovascular (CV) risk, according to an announcement from manufacturer Esperion





中文字典-英文字典  2005-2009